v3.20.1

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash	$ 14,117	$ 18,871
Total current assets	14,117	18,871
Property, plant and equipment, net of depreciation	126	618
Total Assets	14,243	19,489
Current liabilities:
Accounts payable	907,837	895,246
Accrued interest payable	1,796,783	1,457,543
Accrued expenses	50,303
Notes payable, related party	35,000	35,000
Notes payable	325,035	125,005
Convertible notes payable, net of discount and issuance costs of $0 and $35,414 as of September 30, 2019 and December 31, 2018	5,411,000	5,355,586
Total liabilities	8,525,958	7,868,380
Commitments and contingencies
Stockholders' deficiency:
Preferred stock, value
Common stock, $0.00001 par value; 500,000,000 shares authorized; 4,231,460 shares issued and outstanding at September 30, 2019 and December 31, 2018	43	43
Additional paid in capital	4,685,453	4,685,453
Accumulated deficit	(13,136,794)	(12,473,436)
Accumulated other comprehensive loss	(60,418)	(60,952)
Total stockholders' deficiency	(8,511,715)	(7,848,891)
Total Liabilities and Stockholders' equity (deficiency)	14,243	19,489
Series A Convertible Preferred Stock [Member]
Stockholders' deficiency:
Preferred stock, value	1	1
Total stockholders' deficiency	1	1
Series B Convertible Preferred Stock [Member]
Stockholders' deficiency:
Preferred stock, value

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Accelerated Pharma, Inc. 10-Q